Potency assessment of IFNγ-producing SARS-CoV-2- specific T cells from COVID-19 convalescent subjects
Fecha
2023Autor
Versión
Acceso abierto / Sarbide irekia
Tipo
Artículo / Artikulua
Versión
Versión publicada / Argitaratu den bertsioa
Identificador del proyecto
Gobierno de Navarra//0011-3597-2020-000006
Impacto
|
10.26508/lsa.202201759
Resumen
The development of new therapies for COVID-19 high-risk patients remains necessary to prevent additional deaths. Here, we
studied the phenotypical and functional characteristics of IFN-γ
producing-SARS-CoV-2-specific T cells (SC2-STs), obtained from
12 COVID-19 convalescent donors, to determine their potency as
an off-the-shelf T cell therapy product. We found that these cells
present mainly ...
[++]
The development of new therapies for COVID-19 high-risk patients remains necessary to prevent additional deaths. Here, we
studied the phenotypical and functional characteristics of IFN-γ
producing-SARS-CoV-2-specific T cells (SC2-STs), obtained from
12 COVID-19 convalescent donors, to determine their potency as
an off-the-shelf T cell therapy product. We found that these cells
present mainly an effector memory phenotype, characterized by
the basal expression of cytotoxicity and activation markers, including granzyme B, perforin, CD38, and PD-1. We demonstrated
that SC2-STs could be expanded and isolated in vitro, and they
exhibited peptide-specific cytolytic and proliferative responses
after antigenic re-challenge. Collectively, these data demonstrate
that SC2-STs can be a suitable candidate for the manufacture of a
T cell therapy product aimed to treat severe COVID-19. [--]
Materias
Covid 19,
SC2-STs,
T cell therapy
Editor
Life Science Alliance
Publicado en
Life Science Alliance, 6(6), e202201759
Departamento
Universidad Pública de Navarra. Departamento de Ciencias de la Salud /
Nafarroako Unibertsitate Publikoa. Osasun Zientziak Saila
Versión del editor
Entidades Financiadoras
This study was supported by the Department of University, Innovation and Digital Transformation of Government of Navarra, with the grant 0011-3597-2020-000006.